The medical management of inflammatory bowel disease (IBD) in patients with advanced liver disease or after liver transplantation (LT) can be challenging due to the increased risk of bacterial and opportunistic infections. Although anti-tumor necrosis factor (TNF) agents are widely used in the treatment of moderateto-severe IBD in the general population, they are associated with an increased risk for systemic fungal infections, reactivation of hepatitis B virus and latent tuberculosis, and other opportunistic infections to which LT recipients are particularly susceptible.
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(1) LT recipients treated with anti-TNF agents have been reported to have several infections, posttransplant lymphoproliferative disorder, and drug-induced lupus. (2) Vedolizumab (VDZ) is a US Food and Drug Administration-approved humanized monoclonal antibody antagonist of the alpha 4 -beta 7 integrin, used for the treatment of IBD. Alpha 4 -beta 7 integrin blockade specifically prevents leukocyte trafficking into gastrointestinal tissue. A very low (nearly nil) incidence of bacterial, mycobacterial, occult viral, and other opportunistic infections were reported in VDZ clinical trials and meta-analyses. (3) (4) (5) Mounting safety evidence paired with a mechanism specifically targeting the intestine suggests VDZ may offer an attractive option for moderate-to-severe IBD in solid organ transplant recipients. We report our institution's experience using VDZ in LT recipients with moderate-to-severe IBD.
Patients and Methods

PATIENTS
A waiver of consent was provided by the local institutional review board to conduct a retrospective search of the electronic LT database at the University of Michigan Health System. Between January 2014 and March 2016, we identified adult LT recipients with a diagnosis of IBD and exposure to VDZ using an Electronic Medical Record Search tool combined with a manual chart review. The adult immunosuppressive regimen used in our center consists of tacrolimus, mycophenolate, and tapering doses of corticosteroids. Selected individuals with renal insufficiency at the time of LT may receive basiliximab induction doses at days 1 and 4 with a delay in the initiation of tacrolimus to day 3 or 4. The target tacrolimus trough levels are 6-10 ng/mL through month 3 and 4-8 ng/mL thereafter. Corticosteroids are typically discontinued by month 3 in patients with viral hepatitis but are maintained at 5-10 mg/day through year 1 in patients with primary sclerosing cholangitis (PSC) and autoimmune liver disease.
MEASURES OF VDZ EFFICACY AND SAFETY
Corticosteroid dose over time was assessed for each patient in relationship to VDZ initiation; we considered 9 mg of budesonide equivalent to 20 mg of prednisone daily. Corticosteroids used solely as part of antirejection regimens were not included in the IBDAbbreviations: ADA, adalimumab; ALT, alanine aminotransferase; AZA, azathioprine; BMI, body mass index; bid, twice daily; CD, Crohn's disease; CMV, cytomegalovirus; D/R, donor/recipient; HBcAb, hepatitis B core antibody; HCV, hepatitis C virus; IBD, inflammatory bowel disease; IFX, infliximab; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; NA, not available; NR, nonresponder; OLT, orthotopic liver transplantation; PSC, primary sclerosing cholangitis; PTC, percutaneous transhepatic cholangiography; Resp, responder; TNF, tumor necrosis factor; UC, ulcerative colitis; VDZ, vedolizumab. related corticosteroid assessment but were recorded separately. Clinical improvement in IBD activity was defined using the gastroenterologist's global assessment of clinical disease activity at 3, 6, and 12 months following VDZ initiation as reflected in provider documentation within the medical record. When available, endoscopic response was defined as an improvement of mucosal inflammation on posttreatment endoscopy. Treatment failure was defined as the need for colectomy due to IBD activity, insufficient clinical response by physician global assessment, persistent pulses of systemic corticosteroids following VDZ initiation, the development of new fistulizing disease, or transitioning to an alternative treatment. Infections were categorized as bacterial, fungal, or viral based on isolated pathogenic organisms.
Results
PATIENT CHARACTERISTICS
There were 10 LT recipients with moderate-to-severe IBD (8 ulcerative colitis [UC] and 2 Crohn's disease [CD]) who received VDZ therapy between 2014 and 2016 (Table 1 ). Both patients with CD had undergone a prior ileocolonic resection. Of those with UC, 6 patients had pancolitis, whereas 2 had left-sided colitis. Three patients were diagnosed with new-onset IBD after LT. Four patients had previous exposure to anti-TNF agents, 2 had received agents prior to LT and 2 had received agents after LT prior to VDZ therapy. VDZ was administered by standard induction protocol of 300 mg at weeks 0, 2, and 6 and then every 8 weeks thereafter. Two patients ultimately underwent shortening of the VDZ infusion interval to every 4 weeks due to ongoing disease activity.
Notably, 3 patients with cirrhosis underwent transplant while receiving VDZ without interruption. At the time of VDZ initiation, all patients were receiving IBD-related corticosteroids, 8 were receiving aminosalicylates, and 3 were on azathioprine (AZA) or mycophenolate mofetil to treat IBD. PSC was the most common reason for transplantation (9/10). Three patients (patients 4, 7, and 9) experienced recurrent PSC prior to VDZ start; no patients developed recurrent PSC while using VDZ. One patient was transplanted for hepatitis C virus (HCV)-related cirrhosis and underwent successful eradication with directacting antiviral therapy prior to VDZ. All donor grafts were from deceased donors.
IBD TREATMENT OUTCOMES
The median duration of observation while using VDZ was 13.1 months (range, 6.2-24.5). After 6 and then 12 months of treatment, 7/10 and later 6/10 patients on VDZ had maintained clinical improvement (Table 2) . Treatment failure occurred in 4 patients: 2 patients with UC requiring colectomy at 6 and 11 months (patients 9 and 7); 1 patient with CD who developed new perianal fistulas (patient 8); and 1 patient with moderate UC continuing to require prednisone for adequate clinical control (patient 10). One of the 6 responders (Resp) required more frequent VDZ dosing (every 4 weeks) to maintain clinical response (patient 4).
All patients were using IBD-related steroids at VDZ initiation. The median daily corticosteroid dose immediately prior to VDZ start was 25 mg (range, 20-60 mg). At 6 months following VDZ induction, 1/10 patients was receiving < 50% original steroid dose, while 4/10 eliminated all IBD-related steroids. At 12 months following induction in patients still using VDZ, 3/10 patients were receiving < 50% original steroid dose and 3/10 patients eliminated all IBD-related steroids. Only 2/10 patients received steroids for graftrelated immunosuppression during any time in the first year after start of VDZ, with dose ranging from 5 to 10 mg prednisone daily. Of those patients who continued VDZ, 5/8 demonstrated endoscopic improvement at 6-12 months following induction.
INFECTIOUS COMPLICATIONS BEFORE AND AFTER VDZ
During the exposure to VDZ, 5 patients experienced a total of 11 infections (4 cholangitis, 4 Clostridium difficile colitis, 2 empyema, and 1 pneumonia Finally, a third patient with UC and PSC (patient 3) underwent his third LT for anti-TNF therapy-related cholestatic liver injury (MELD, 35) while receiving VDZ for 5 months before LT. Postoperatively, his course was complicated by a leak of his hepaticojejunsotmy requiring surgical repair. Each of these patients remains on VDZ at the time of writing. As described in Table 1 , 9 of the 10 patients received maintenance tacrolimus-based immunosuppression while receiving VDZ. One patient received basiliximab induction at the time of LT (patient 5); notably, this patient was using VDZ at the time of LT. All other patients had been given standard doses of tacrolimus, mycophenolate, and corticosteroids per protocol. The daily doses of tacrolimus were stable along with stable blood levels during VDZ administration. Notably, liver biochemistry levels were stable in LT recipients receiving VDZ, and no patients had evidence of rejection during a median post-LT follow-up of 13.1 months following first exposure to VDZ. In addition, there were no episodes of calcineurin inhibitor-related neurotoxicity or nephrotoxicity.
Discussion
VDZ was a safe and effective steroid-sparing therapy for the treatment of moderate-to-severe IBD among 10 LT recipients seen at a single transplant center over a 2-year period. Clinical improvement was observed in 7/10 and 6/10 patients after 6 and 12 months of therapy, respectively. At 12 months, 6/10 patients were able to significantly reduce or discontinue IBD-related corticosteroids. However, we note that 5 patients experienced an infection following VDZ initiation. The majority of infections occurred in patients with prior episodes (Clostridium difficile and PTC tube-related cholangitis) or in the immediate posttransplant period (empyema). All infections responded to antibiotics, and there were no deaths. Furthermore, patients undergoing transplant while using VDZ experienced no opportunistic fungal, viral, or mycobacterial infections. Although difficult to definitively confirm, we do not believe any of the observed bacterial infections were the result of VDZ use.
The ability to target the intestinal tract using VDZ provides an attractive option in LT recipients already receiving antirejection immunosuppressive regimens, and it may be a uniquely effective therapy in special IBD populations. The principle limitations of this retrospective, single-center study are the small sample size, limited duration of follow-up, and unaccounted decision bias. However, patients with liver disease are typically excluded from clinical trials of IBD therapeutics, giving value to observational study. Going forward, prospective registry studies are needed to better understand the longterm efficacy and safety of intestine-specific treatments in the expanding population of solid organ transplant candidates and recipients.
